Jennifer Taylor-Cousar
Concepts (330)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 124 | 2026 | 1124 | 22.950 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 75 | 2026 | 347 | 15.380 |
Why?
| | Quinolones | 37 | 2026 | 174 | 9.540 |
Why?
| | Aminophenols | 48 | 2026 | 175 | 9.360 |
Why?
| | Benzodioxoles | 34 | 2026 | 138 | 6.880 |
Why?
| | Chloride Channel Agonists | 30 | 2026 | 98 | 5.070 |
Why?
| | Indoles | 27 | 2026 | 472 | 4.230 |
Why?
| | Sinusitis | 13 | 2026 | 239 | 3.950 |
Why?
| | Rhinitis | 11 | 2026 | 173 | 3.160 |
Why?
| | Pyridines | 21 | 2026 | 560 | 2.710 |
Why?
| | Pyrazoles | 24 | 2026 | 482 | 2.620 |
Why?
| | Pyrrolidines | 18 | 2026 | 109 | 2.480 |
Why?
| | Olfaction Disorders | 8 | 2025 | 70 | 2.260 |
Why?
| | Drug Combinations | 27 | 2026 | 365 | 2.200 |
Why?
| | Aminopyridines | 6 | 2025 | 107 | 2.040 |
Why?
| | Mutation | 34 | 2024 | 4006 | 1.890 |
Why?
| | Membrane Transport Modulators | 3 | 2020 | 7 | 1.810 |
Why?
| | Fetal Therapies | 2 | 2026 | 47 | 1.800 |
Why?
| | Pongo pygmaeus | 3 | 2024 | 7 | 1.780 |
Why?
| | Pregnancy Complications | 6 | 2025 | 577 | 1.770 |
Why?
| | Ape Diseases | 3 | 2024 | 7 | 1.550 |
Why?
| | Reproductive Health | 9 | 2024 | 91 | 1.360 |
Why?
| | Azithromycin | 7 | 2021 | 98 | 1.280 |
Why?
| | Humans | 133 | 2026 | 141284 | 1.260 |
Why?
| | Quality of Life | 18 | 2026 | 3024 | 1.260 |
Why?
| | Pregnancy Outcome | 6 | 2024 | 453 | 1.250 |
Why?
| | Pregnancy | 22 | 2026 | 7035 | 1.230 |
Why?
| | Adult | 66 | 2026 | 39319 | 1.090 |
Why?
| | Respiratory System Agents | 2 | 2020 | 23 | 1.090 |
Why?
| | Reproductive Techniques, Assisted | 3 | 2025 | 41 | 1.080 |
Why?
| | Sexual Health | 6 | 2025 | 67 | 1.070 |
Why?
| | Parents | 5 | 2024 | 1439 | 1.070 |
Why?
| | Female | 78 | 2026 | 75814 | 1.000 |
Why?
| | Quinolines | 8 | 2026 | 169 | 0.960 |
Why?
| | Paranasal Sinuses | 5 | 2024 | 84 | 0.950 |
Why?
| | Pseudomonas Infections | 9 | 2024 | 225 | 0.870 |
Why?
| | Chronic Disease | 15 | 2026 | 1807 | 0.860 |
Why?
| | Drug Approval | 3 | 2024 | 87 | 0.860 |
Why?
| | Fetal Diseases | 1 | 2026 | 180 | 0.850 |
Why?
| | Pregnancy Rate | 3 | 2021 | 68 | 0.840 |
Why?
| | Anti-Bacterial Agents | 12 | 2024 | 1866 | 0.840 |
Why?
| | Respiratory Mucosa | 2 | 2025 | 324 | 0.830 |
Why?
| | Pongo | 2 | 2021 | 7 | 0.820 |
Why?
| | Treatment Outcome | 25 | 2026 | 11216 | 0.770 |
Why?
| | Prospective Studies | 18 | 2026 | 7805 | 0.730 |
Why?
| | Male | 61 | 2026 | 70140 | 0.700 |
Why?
| | Lung Transplantation | 1 | 2024 | 322 | 0.680 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 1078 | 0.680 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 20 | 0.670 |
Why?
| | Glucose Intolerance | 2 | 2025 | 146 | 0.670 |
Why?
| | Sputum | 6 | 2026 | 310 | 0.650 |
Why?
| | Sweat | 9 | 2025 | 47 | 0.640 |
Why?
| | Compassionate Use Trials | 1 | 2019 | 7 | 0.630 |
Why?
| | Aerosols | 1 | 2020 | 177 | 0.620 |
Why?
| | Lung | 9 | 2023 | 4051 | 0.610 |
Why?
| | Smell | 4 | 2025 | 132 | 0.610 |
Why?
| | Transcriptome | 1 | 2025 | 1007 | 0.600 |
Why?
| | Fertility | 3 | 2025 | 165 | 0.590 |
Why?
| | Precision Medicine | 2 | 2021 | 435 | 0.590 |
Why?
| | Pseudomonas aeruginosa | 9 | 2022 | 357 | 0.590 |
Why?
| | Genetic Therapy | 4 | 2025 | 315 | 0.590 |
Why?
| | Breast Feeding | 3 | 2025 | 441 | 0.560 |
Why?
| | Young Adult | 26 | 2026 | 13727 | 0.560 |
Why?
| | Forced Expiratory Volume | 11 | 2023 | 483 | 0.550 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 254 | 0.530 |
Why?
| | Drug Monitoring | 6 | 2020 | 396 | 0.530 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 27 | 0.520 |
Why?
| | Glucose Tolerance Test | 2 | 2025 | 367 | 0.510 |
Why?
| | Child | 24 | 2025 | 22390 | 0.500 |
Why?
| | Rifampin | 1 | 2017 | 81 | 0.500 |
Why?
| | Leukocyte Elastase | 2 | 2026 | 76 | 0.490 |
Why?
| | Biomedical Research | 3 | 2024 | 684 | 0.490 |
Why?
| | Pongo abelii | 1 | 2016 | 1 | 0.490 |
Why?
| | Chlorides | 8 | 2025 | 137 | 0.480 |
Why?
| | Adolescent | 27 | 2026 | 22116 | 0.460 |
Why?
| | Sildenafil Citrate | 2 | 2014 | 59 | 0.460 |
Why?
| | Surveys and Questionnaires | 11 | 2025 | 5948 | 0.440 |
Why?
| | Bronchiectasis | 1 | 2016 | 111 | 0.440 |
Why?
| | Tobramycin | 5 | 2019 | 52 | 0.430 |
Why?
| | Infertility, Male | 2 | 2025 | 62 | 0.430 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2020 | 656 | 0.400 |
Why?
| | Respiratory Function Tests | 6 | 2025 | 558 | 0.370 |
Why?
| | Double-Blind Method | 10 | 2025 | 1992 | 0.370 |
Why?
| | Lactation | 3 | 2022 | 190 | 0.360 |
Why?
| | Contraception Behavior | 2 | 2025 | 101 | 0.360 |
Why?
| | Homozygote | 4 | 2021 | 199 | 0.340 |
Why?
| | Genotype | 8 | 2025 | 1854 | 0.340 |
Why?
| | Contraception | 2 | 2025 | 165 | 0.330 |
Why?
| | Drug Interactions | 4 | 2020 | 404 | 0.310 |
Why?
| | International Cooperation | 2 | 2020 | 195 | 0.300 |
Why?
| | Hypoventilation | 1 | 2009 | 12 | 0.300 |
Why?
| | Alleles | 8 | 2025 | 878 | 0.300 |
Why?
| | Respiratory Muscles | 1 | 2009 | 35 | 0.300 |
Why?
| | ABO Blood-Group System | 1 | 2009 | 53 | 0.290 |
Why?
| | Blood Glucose | 3 | 2025 | 2286 | 0.290 |
Why?
| | Parenting | 2 | 2023 | 319 | 0.280 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1035 | 0.280 |
Why?
| | Animals | 11 | 2026 | 37328 | 0.270 |
Why?
| | Tomography, X-Ray Computed | 4 | 2022 | 2765 | 0.260 |
Why?
| | Needs Assessment | 2 | 2020 | 388 | 0.260 |
Why?
| | Asthma | 3 | 2024 | 1911 | 0.250 |
Why?
| | Middle Aged | 21 | 2025 | 34658 | 0.250 |
Why?
| | United States | 11 | 2025 | 15298 | 0.240 |
Why?
| | Sexual Behavior | 3 | 2025 | 493 | 0.240 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 619 | 0.240 |
Why?
| | Phenylpropionates | 1 | 2025 | 21 | 0.240 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 124 | 0.230 |
Why?
| | Airway Remodeling | 1 | 2025 | 69 | 0.230 |
Why?
| | Off-Label Use | 1 | 2025 | 51 | 0.230 |
Why?
| | Oligonucleotides, Antisense | 1 | 2025 | 110 | 0.220 |
Why?
| | Biomarkers | 6 | 2026 | 4180 | 0.220 |
Why?
| | Fertility Preservation | 1 | 2024 | 53 | 0.210 |
Why?
| | Minimal Clinically Important Difference | 1 | 2023 | 24 | 0.210 |
Why?
| | Infant, Newborn | 4 | 2024 | 6270 | 0.210 |
Why?
| | Food Preferences | 1 | 2025 | 124 | 0.210 |
Why?
| | Orphan Drug Production | 1 | 2023 | 5 | 0.200 |
Why?
| | Pregnancy, Unplanned | 2 | 2023 | 46 | 0.200 |
Why?
| | C-Reactive Protein | 2 | 2018 | 416 | 0.200 |
Why?
| | Sexually Transmitted Diseases | 1 | 2025 | 166 | 0.200 |
Why?
| | Patient Selection | 2 | 2019 | 685 | 0.200 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 116 | 0.190 |
Why?
| | Ion Transport | 2 | 2021 | 62 | 0.190 |
Why?
| | Respiratory Tract Diseases | 1 | 2024 | 180 | 0.190 |
Why?
| | Body Height | 1 | 2023 | 200 | 0.190 |
Why?
| | Neonatal Screening | 1 | 2024 | 172 | 0.190 |
Why?
| | Puberty | 1 | 2023 | 152 | 0.190 |
Why?
| | Azabicyclo Compounds | 1 | 2021 | 6 | 0.180 |
Why?
| | Epoxide Hydrolases | 1 | 2021 | 13 | 0.180 |
Why?
| | Inflammation | 3 | 2026 | 2840 | 0.180 |
Why?
| | Enzyme Activators | 1 | 2021 | 8 | 0.180 |
Why?
| | Psychometrics | 1 | 2026 | 736 | 0.180 |
Why?
| | Benzoates | 1 | 2021 | 49 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2047 | 0.180 |
Why?
| | RNA, Messenger | 3 | 2022 | 2815 | 0.170 |
Why?
| | Men's Health | 1 | 2020 | 6 | 0.170 |
Why?
| | Cyclopropanes | 3 | 2026 | 75 | 0.170 |
Why?
| | Infertility | 1 | 2021 | 55 | 0.170 |
Why?
| | Endoscopy | 4 | 2024 | 327 | 0.170 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 367 | 0.170 |
Why?
| | Women's Rights | 1 | 2020 | 4 | 0.160 |
Why?
| | Disease Progression | 5 | 2020 | 2808 | 0.160 |
Why?
| | Communicable Disease Control | 1 | 2020 | 86 | 0.160 |
Why?
| | Virulence Factors | 2 | 2014 | 162 | 0.160 |
Why?
| | Retrospective Studies | 10 | 2024 | 16447 | 0.160 |
Why?
| | Patient Acceptance of Health Care | 2 | 2025 | 874 | 0.160 |
Why?
| | Cataract | 1 | 2022 | 223 | 0.160 |
Why?
| | Aztreonam | 2 | 2016 | 11 | 0.160 |
Why?
| | Colistin | 1 | 2019 | 10 | 0.150 |
Why?
| | Neutrophils | 3 | 2016 | 1113 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2024 | 5222 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2025 | 1395 | 0.150 |
Why?
| | Sexism | 1 | 2020 | 69 | 0.150 |
Why?
| | Medication Therapy Management | 1 | 2020 | 78 | 0.150 |
Why?
| | Receptors, Interleukin-8B | 1 | 2018 | 24 | 0.150 |
Why?
| | Health Status | 1 | 2023 | 822 | 0.140 |
Why?
| | Research Design | 1 | 2024 | 1105 | 0.140 |
Why?
| | Administration, Oral | 1 | 2020 | 825 | 0.140 |
Why?
| | Mental Health | 1 | 2024 | 756 | 0.140 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2904 | 0.140 |
Why?
| | Pyrimidines | 1 | 2021 | 510 | 0.140 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 451 | 0.130 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.130 |
Why?
| | Pregnancy, High-Risk | 1 | 2017 | 15 | 0.130 |
Why?
| | Leukocytes | 1 | 2018 | 293 | 0.130 |
Why?
| | HEK293 Cells | 1 | 2020 | 738 | 0.130 |
Why?
| | Risk Assessment | 3 | 2021 | 3522 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2929 | 0.130 |
Why?
| | Biological Availability | 1 | 2017 | 137 | 0.130 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 388 | 0.130 |
Why?
| | Research | 1 | 2020 | 434 | 0.130 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 70 | 0.130 |
Why?
| | Risk Adjustment | 1 | 2017 | 81 | 0.120 |
Why?
| | Prognosis | 2 | 2022 | 4080 | 0.120 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 237 | 0.120 |
Why?
| | Recovery of Function | 1 | 2020 | 684 | 0.120 |
Why?
| | Health Services Accessibility | 2 | 2024 | 1030 | 0.120 |
Why?
| | Albuterol | 1 | 2016 | 75 | 0.120 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1761 | 0.120 |
Why?
| | Pharmacogenetics | 1 | 2017 | 167 | 0.120 |
Why?
| | Attitude of Health Personnel | 1 | 2023 | 1178 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 501 | 0.110 |
Why?
| | Interferons | 1 | 2016 | 194 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2016 | 222 | 0.110 |
Why?
| | Epithelial Cells | 2 | 2020 | 1105 | 0.110 |
Why?
| | Pilot Projects | 2 | 2020 | 1820 | 0.110 |
Why?
| | Machine Learning | 1 | 2020 | 555 | 0.110 |
Why?
| | Bronchodilator Agents | 1 | 2016 | 196 | 0.110 |
Why?
| | Child, Preschool | 3 | 2024 | 11511 | 0.110 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2014 | 36 | 0.110 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 390 | 0.110 |
Why?
| | Metalloproteases | 1 | 2014 | 42 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 396 | 0.110 |
Why?
| | Quorum Sensing | 1 | 2014 | 74 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2366 | 0.100 |
Why?
| | Body Mass Index | 2 | 2023 | 2390 | 0.100 |
Why?
| | Preconception Care | 2 | 2025 | 48 | 0.100 |
Why?
| | Administration, Inhalation | 3 | 2022 | 594 | 0.100 |
Why?
| | Neutrophil Activation | 1 | 2013 | 83 | 0.100 |
Why?
| | Wound Infection | 1 | 2013 | 37 | 0.100 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 62 | 0.090 |
Why?
| | Condoms | 2 | 2025 | 101 | 0.090 |
Why?
| | Cellular Structures | 1 | 2011 | 6 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 111 | 0.090 |
Why?
| | Comorbidity | 1 | 2016 | 1671 | 0.090 |
Why?
| | Drug Therapy, Combination | 3 | 2021 | 1043 | 0.090 |
Why?
| | Extracellular Space | 1 | 2011 | 128 | 0.090 |
Why?
| | Microbial Viability | 1 | 2011 | 91 | 0.090 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 713 | 0.080 |
Why?
| | Patient Admission | 1 | 2012 | 203 | 0.080 |
Why?
| | Risk Factors | 3 | 2020 | 10490 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 571 | 0.080 |
Why?
| | Infant | 1 | 2024 | 9820 | 0.080 |
Why?
| | Survival Rate | 2 | 2018 | 1979 | 0.080 |
Why?
| | Blood Group Antigens | 1 | 2009 | 16 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2091 | 0.070 |
Why?
| | Aged | 5 | 2024 | 24836 | 0.070 |
Why?
| | Mucus | 1 | 2009 | 78 | 0.070 |
Why?
| | Burns | 1 | 2013 | 350 | 0.070 |
Why?
| | Mass Screening | 1 | 2016 | 1309 | 0.070 |
Why?
| | Inpatients | 1 | 2012 | 513 | 0.070 |
Why?
| | ADP Ribose Transferases | 1 | 2007 | 9 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.070 |
Why?
| | Furin | 1 | 2007 | 14 | 0.070 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2007 | 18 | 0.070 |
Why?
| | Time Factors | 3 | 2024 | 6951 | 0.070 |
Why?
| | Cyclic GMP | 1 | 2007 | 91 | 0.070 |
Why?
| | Bacterial Toxins | 1 | 2007 | 104 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2600 | 0.060 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 184 | 0.060 |
Why?
| | Phenotype | 1 | 2015 | 3172 | 0.060 |
Why?
| | Sulfones | 1 | 2007 | 127 | 0.060 |
Why?
| | Survivors | 1 | 2010 | 501 | 0.060 |
Why?
| | Registries | 3 | 2023 | 2205 | 0.060 |
Why?
| | Respiratory System | 1 | 2007 | 155 | 0.060 |
Why?
| | Quinoxalines | 1 | 2025 | 67 | 0.060 |
Why?
| | European Union | 1 | 2024 | 11 | 0.060 |
Why?
| | Piperazines | 1 | 2007 | 375 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2009 | 689 | 0.050 |
Why?
| | Reproductive Health Services | 1 | 2023 | 18 | 0.050 |
Why?
| | Standard of Care | 1 | 2024 | 77 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 2098 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 197 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5653 | 0.050 |
Why?
| | Nose | 1 | 2023 | 65 | 0.050 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2024 | 60 | 0.050 |
Why?
| | Cell Separation | 2 | 2016 | 309 | 0.050 |
Why?
| | Deoxyribonuclease I | 1 | 2022 | 40 | 0.050 |
Why?
| | Saline Solution, Hypertonic | 1 | 2022 | 41 | 0.050 |
Why?
| | Rare Diseases | 1 | 2023 | 111 | 0.050 |
Why?
| | Sex Education | 1 | 2022 | 32 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 269 | 0.050 |
Why?
| | Hot Flashes | 1 | 2023 | 87 | 0.050 |
Why?
| | Contraceptive Agents | 1 | 2022 | 66 | 0.050 |
Why?
| | Iron | 1 | 2024 | 324 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 2 | 2014 | 367 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2122 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2024 | 303 | 0.040 |
Why?
| | Biofilms | 2 | 2014 | 274 | 0.040 |
Why?
| | Nutritional Status | 1 | 2023 | 357 | 0.040 |
Why?
| | Genetic Counseling | 1 | 2021 | 81 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 275 | 0.040 |
Why?
| | Attitude | 1 | 2022 | 257 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 859 | 0.040 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2020 | 28 | 0.040 |
Why?
| | Longevity | 1 | 2021 | 174 | 0.040 |
Why?
| | Menopause | 1 | 2023 | 317 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2022 | 1362 | 0.040 |
Why?
| | Tetraspanin 30 | 1 | 2018 | 10 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2022 | 815 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 592 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 168 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 22 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 2055 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 462 | 0.040 |
Why?
| | Ecosystem | 1 | 2023 | 574 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 2529 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2024 | 674 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2026 | 3345 | 0.030 |
Why?
| | trans-Golgi Network | 2 | 2007 | 15 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2016 | 3577 | 0.030 |
Why?
| | Gene Deletion | 1 | 2018 | 384 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2007 | 171 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 320 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 41 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2018 | 4149 | 0.030 |
Why?
| | Genetic Variation | 1 | 2021 | 993 | 0.030 |
Why?
| | Leadership | 1 | 2020 | 388 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 195 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 510 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2023 | 1336 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4599 | 0.030 |
Why?
| | Depression | 1 | 2024 | 1490 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 78 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 910 | 0.030 |
Why?
| | Rats | 1 | 2022 | 5556 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1057 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1322 | 0.020 |
Why?
| | Ciprofloxacin | 1 | 2013 | 26 | 0.020 |
Why?
| | Cohort Studies | 1 | 2023 | 5809 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1505 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 343 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 208 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 367 | 0.020 |
Why?
| | Cell Line | 2 | 2007 | 2863 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 29 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 208 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 448 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 396 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 381 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 7948 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 536 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2069 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2007 | 81 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2007 | 22 | 0.020 |
Why?
| | Epithelial Sodium Channels | 1 | 2007 | 21 | 0.020 |
Why?
| | Guanylate Cyclase | 1 | 2007 | 38 | 0.020 |
Why?
| | Insulin Infusion Systems | 1 | 2012 | 480 | 0.020 |
Why?
| | Sodium | 1 | 2007 | 194 | 0.020 |
Why?
| | Purines | 1 | 2007 | 182 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 550 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2007 | 1059 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 478 | 0.010 |
Why?
| | Mice | 2 | 2013 | 17969 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2012 | 1380 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4414 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2007 | 894 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2165 | 0.010 |
Why?
| | Insulin | 1 | 2012 | 2472 | 0.010 |
Why?
| | Macrophages | 1 | 2007 | 1478 | 0.010 |
Why?
| | Signal Transduction | 1 | 2007 | 5116 | 0.010 |
Why?
|
|
Taylor-Cousar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|